Dusseldorf - Delayed Quote EUR

Eli Lilly and Co (LLY0.DU)

19.60

+0.40

+(2.08%)

At close: 7:31:09 PM GMT+2

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Investor's Business Daily 2 days ago

PFE

LLY

NONOF
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s blockbuster shots.

The Wall Street Journal 2 days ago

LLY
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth

Netflix and DoorDash are two of the seven best stocks where investors can find magnificent profit growth prospects. More than 70% of analysts covering Netflix have buy or overweight ratings on the video streaming service. The consensus estimate for 2025 earnings is $24.76, a 21% increase from last year, according to FactSet.

Investor's Business Daily 5 days ago

ISRG

NFLX

LLY
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week

UnitedHealth shares took a nosedive Thursday after slashing its annual outlook. The healthcare conglomerate posted quarterly earnings that fell short of Wall Street’s expectations and substantially downgraded its projected results for 2025. UnitedHealth—parent of the largest U.S. health insurer—cited higher-than-expected medical costs in its Medicare business, an issue that has affected the entire industry over the past year but had previously not been as significant at UnitedHealth.

The Wall Street Journal 6 days ago

UNH

LLY
Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery

Eli Lilly (NYSE:LLY) experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to enhance therapeutic antibody development, while positive results from their Phase 3 trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence despite the overall flat market performance during the same period. With...

Simply Wall St. 6 days ago

LLY
H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate,

TipRanks 6 days ago

LLY

VKTX
Eli Lilly jumps as results from weight-loss pill study rival competitor’s

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno

TipRanks 6 days ago

LLY

NONOF

NVO
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext

TipRanks 6 days ago

GPCR

LLY

VKTX
How Eli Lilly's GLP-1 pill could transform the weight-loss space

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 7 days ago

LLY

NONOF

NVO
Stocks Rebound Fizzles as Trump Goes on Offensive: Markets Wrap

(Bloomberg) -- A rebound in US stocks evaporated this week after Chair Jerome Powell pushed back on the idea of the Federal Reserve stepping in to bolster markets, rankling President Donald Trump who touted a smattering of deals Thursday. Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceDOGE Places Entire Staff of Federal Homelessness Agency on LeaveHow Did This Suburb Figure Out Mass Transit?Trump Administration Takes Over New York Penn Station RevampWhy t

Bloomberg 7 days ago

UNH

LLY

GOOG
Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

Investor's Business Daily 7 days ago

VKTX

LLY

NONOF
Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs closer to patients seeking to lose weight. Physicians and patients have been hoping for pill versions of popular GLP-1s for weight loss.

The Wall Street Journal 7 days ago

LLY
Eli Lilly (NYSE:LLY) Partners With BigHat And Achieves Phase 3 Success With Orforglipron

Eli Lilly (NYSE:LLY) experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The company's share price was likely influenced by its strategic collaboration with BigHat Biosciences and positive results from its ACHIEVE-1 Phase 3 trial for orforglipron. These positive developments countered the market's broader dip caused by tech sector weaknesses and economic concerns following recent economic tariff suggestions influencing investor sentiments. These...

Simply Wall St. 7 days ago

LLY
UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook

On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock plunges after the company's earnings fell short of analyst expectations. Eli Lilly (LLY) stock surges after positive results about its weight-loss pill trial. Taiwan Semiconductor Manufacturing Company (TSM) stock is in focus after the company reported earnings and maintained its 2025 forecast despite new chip export restrictions. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 7 days ago

LLY

TSM

TSMWF
Eli Lilly stock soars on positive weight-loss pill results

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 7 days ago

HIMS

LLY

NONOF
Lilly confirms date and conference call for first-quarter 2025 financial results announcement

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

PR Newswire 7 days ago

LLY
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to

PR Newswire 7 days ago

LLY
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the

TipRanks 9 days ago

NONOF

NVO

LLY
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv

TipRanks 9 days ago

LLY

NVS

NVSEF
Trump Initiates Chips and Drug Probes Ahead of More Tariffs

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade

Bloomberg 9 days ago

TD

TDBKF

000660.KS

Performance Overview

Return	LLY0.DU	S&P 500 (^GSPC)
YTD	+9.80%	-6.75%
1-Year	+8.55%	+8.15%
3-Year	+3.70%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (LLY0.DU)

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth

The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week

Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery

H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

How Eli Lilly's GLP-1 pill could transform the weight-loss space

Stocks Rebound Fizzles as Trump Goes on Offensive: Markets Wrap

Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results

Eli Lilly (NYSE:LLY) Partners With BigHat And Achieves Phase 3 Success With Orforglipron

UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook

Eli Lilly stock soars on positive weight-loss pill results

Lilly confirms date and conference call for first-quarter 2025 financial results announcement

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

Trump Initiates Chips and Drug Probes Ahead of More Tariffs

Performance Overview